Archive · 8 Sep 2025
Sun Pharma and Lupin Develop Anti-Obesity Pill to Combat Obesity
Imagine lots of people in India are becoming overweight.
To help, two big medicine companies, Sun Pharma and Lupin, are making a pill to help people lose weight.
This is important because many people don't like getting shots for their medicine.
The government is letting them test the pill to make sure it works.
Experts say that these pills need to be taken under the care of a doctor.
Many other companies are also working on similar pills.
These new pills might make it easier and cheaper for people to get help with their weight, but they need to be used carefully.
Sun Pharma and Lupin are creating oral semaglutide pills to address obesity.
Regulatory approvals have been granted for trials and studies.
India's obesity problem may affect 450 million adults by 2050.
Experts are advocating for strict medical oversight.
Generic versions of these pills may soon flood the market.
- Who
- Sun Pharma and Lupin, along with other Indian companies such as Dr. Reddy's Laboratories Ltd and Cipla Ltd
- What
- Are developing affordable anti-obesity pills, specifically oral semaglutide, to address obesity and injection aversion in India.
- When
- Regulatory approvals have been granted; generic versions may flood the market next year.
- Where
- India
- Why
- To address India's growing obesity crisis and make anti-obesity medication more accessible and patient-friendly.
- Companies Involved
- Sun Pharma and Lupin
- Drug Type
- Anti-obesity pill (oral semaglutide)
- Regulatory Status
- Phase III trial (Sun), Bioequivalence study (Lupin)
- Projected Obese Adults in India by 2050
- 450 million
- Expert Recommendation
- Strict medical supervision and avoidance of misuse